Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of Phase 3 clinical data in the Jo
Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Rating) saw a large growth in short interest in September. As of September 30th, there was short interest totalling 4,930,000 shares, a growth of 45.9% from the September 15th total of 3,380,000 shares. Based on an average daily volume of 1,050,000 shares…
Marketreports.info has presented a Global Human Microbiome Market from 2022 to 2030 global study rep
Recent research demonstrating how important the human microbiome is for maintaining good health has led to the founding of many biotech companies hoping to create microbiome-based therapeutics. These five biotech companies all have candidates in clinical trials and are primed to be among the first t…
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it will be presenting data from its ECOSPOR I
DelveInsight’s, “Clostridium Difficile Infections Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and
The Seattle Mariners will be heading to Toronto to face the Blue Jays on Friday in the first game of the best-of-three wild-card playoff series.
The market research for the Microbiome Drugs industry provides details on important product offers, company background, current trends, marketing and
Gasgoo Daily: CALB inks agreement for Chengdu battery base's second phase project Gasgoo Auto News
While Chinese companies churn out new electric cars, local insurance firms think they’re more expensive to cover.
The week in pharma: action, reaction and insight – week to September 23
Is Seres Therapeutics Inc (MCRB) Stock at the Top of the Biotechnology Industry?
Adversity is less terrifying than hope: Seres Therapeutics Inc. (MCRB) SETE News
Upstarts Nio, Xpeng and Li Auto force traditional carmakers to take notice
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced it has completed the rolling submission process fo
Seres' Tie-Up With Huawei Deepens; Latest EV to Be Sold in More Huawei Stores Yicai Global
Huawei launched the flagship Mate 50 in China without 5G internet connectivity after U.S. sanctions cut off the Chinese tech company from key components.
Seres Therapeutics Announces Completion of Rolling Bla Submission to FDA for Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection.<br>Seres Therapeutics Inc - Anticipated Product Launch in First Half of 2023.<br>
Seres Therapeutics (NASDAQ:MCRB) Sees Strong Trading Volume After Analyst Upgrade